- Home
- UNM vs MRNA Comparison
UNM vs MRNA Comparison
Compare UNM & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNM | MRNA |
|---|---|---|
| Founded | 1848 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 11.5B |
| IPO Year | 1986 | 2018 |
Fundamental Metrics
Financial Performance| Metric | UNM | MRNA |
|---|---|---|
| Price | $75.90 | $44.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 13 |
| Target Price | ★ $95.09 | $32.75 |
| AVG Volume (30 Days) | 1.1M | ★ 14.2M |
| Earning Date | 02-05-2026 | 02-13-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.18 | N/A |
| Revenue | ★ $13,068,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | $3.19 | $3.18 |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $66.81 | $22.28 |
| 52 Week High | $84.48 | $55.20 |
Technical Indicators
Market Signals| Indicator | UNM | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 62.09 |
| Support Level | $75.35 | $39.21 |
| Resistance Level | $77.18 | $51.18 |
| Average True Range (ATR) | 1.53 | 3.33 |
| MACD | -0.37 | 0.43 |
| Stochastic Oscillator | 14.12 | 53.96 |
Price Performance
Historical ComparisonAbout UNM Unum Group
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The majority of the revenue is earned from the Unum USA segment. The firm markets its products through brokers.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.